Bioenvision’s leukaemia treatment gains positive opinion

pharmafile | March 1, 2006 | News story | Sales and Marketing |   

Bioenvision has received a positive opinion from the European Medicines Agency for Evoltra (clofarabine), the first drug specifically developed for children with multiple relapsed or refractory leukaemia.

The drug is expected to gain final marketing approval within the next three months to treat acute lymphoblastic leukaemia (ALL) in children who have relapsed or are refractory to at least two prior regimens.

Bioenvision will market Evoltra throughout all 25 member states of the EU and has licensed it to Genzyme to develop and market in the US and Canada under the brand name Clolar.

Advertisement

 

Related Content

No items found
The Gateway to Local Adoption Series

Latest content